Hormone Receptor–Positive
Hormone Receptor–Positive Medications and Resources
Hormone Receptor–Positive breast cancer can bring many new terms, tests, and treatment choices. This collection helps patients and caregivers browse condition-aligned medications, product pages, and plain-language guides connected to HR positive breast cancer care. Use it to compare therapy classes, forms, and related resources before discussing next steps with an oncology team.
Clinicians often describe this subtype as ER positive breast cancer, PR positive breast cancer, or ER/PR positive breast cancer. These labels mean cancer cells have receptors that may respond to estrogen or progesterone signals. Treatment planning can vary by stage, menopause status, HER2 status, prior therapy, side effects, and personal goals.
What Hormone Receptor–Positive care options include
This category centers on medicines and resources used around hormone receptor positive breast cancer treatment. Many listed options relate to endocrine therapy, which means treatment that lowers hormone activity or blocks hormone signals. Some products are daily tablets. Others are injections or targeted add-ons used with hormonal therapy for breast cancer.
You can browse the condition-focused page for Hormone Receptor Positive Breast Cancer when you want a wider view of related listings. The broader Breast Cancer collection can help when receptor status, stage, and product class are still being sorted.
Common groups in this collection include:
- Aromatase inhibitors, such as anastrozole, letrozole, or exemestane, which lower estrogen production after menopause.
- SERMs, such as tamoxifen, which block estrogen receptors in some tissues.
- SERDs, such as fulvestrant, which block and degrade estrogen receptors.
- CDK4/6 inhibitors, such as palbociclib, ribociclib, or abemaciclib, which may be paired with endocrine therapy.
- Condition pages that separate early stage HR+ breast cancer, HER2-negative disease, and other related settings.
Why it matters: Receptor status helps organize options, but it never replaces an individualized oncology plan.
How to compare hormone therapy and targeted medicine listings
Start with the medicine class named in the treatment plan. A product page for Anastrozole may be relevant when an aromatase inhibitor is being considered. The guide on Anastrozole Uses and Side Effects can help you prepare practical questions about common effects, monitoring, and day-to-day use.
For receptor-degrading therapy, Fulvestrant is a representative injectable option. For targeted add-ons, compare Ibrance, Kisqali, and Verzenio as separate product listings. These pages should be used for browsing product details, not for changing treatment without clinician guidance.
When comparing listings, look for the details that affect real use:
- Class: endocrine therapy, aromatase inhibitors, SERMs, SERDs, or CDK4/6 inhibitors.
- Form: tablet, capsule, or injection, including whether clinic administration may be needed.
- Combination plan: whether the medicine is used alone or with another therapy.
- Monitoring: lab checks, symptom tracking, or other follow-up your clinician may request.
- Handling: storage, refill timing, and packaging details shown on the product page.
Quick tip: Keep your medication list nearby when comparing product pages and guides.
Stage, HER2 status, and menopause context
Hormone Receptor–Positive disease can appear in different care settings. Early stage HR+ breast cancer may involve surgery, radiation, chemotherapy, adjuvant endocrine therapy, or neoadjuvant endocrine therapy, depending on the full case. Metastatic HR+ breast cancer often focuses on longer-term disease control and symptom management.
Stage-specific browsing is easier when you separate the condition pages first. The Early Breast Cancer page can help you scan resources linked to earlier treatment settings. If HER2 results are part of the report, compare HER2 Negative Breast Cancer and HER2 Positive Breast Cancer pages so the category path matches the diagnosis wording.
Menopause status also shapes many discussions. Postmenopausal patients may hear more about aromatase inhibitors. Premenopausal patients may hear about ovarian suppression therapy, which reduces ovarian estrogen production, often paired with another hormone-blocking medicine. Your oncology team can explain why one approach fits better than another.
Patient guides that explain common options
Some visitors need product pages first. Others need a short explainer before comparing medications. The article on Ibrance and Palbociclib explains how one CDK4/6 medicine is discussed in breast cancer care. The Ibrance Access Guide focuses more on practical preparation and patient navigation.
For another CDK4/6 option, the Ribociclib Patient Guide may help you understand common monitoring conversations. If an aromatase inhibitor is part of the plan, Exemestane Tablets offers a focused resource on that medicine type.
These guides are useful for learning vocabulary before appointments. They should not be used to compare survival rates, predict outcomes, or decide whether PR positive breast cancer is better or worse. Prognosis depends on many factors, including stage, grade, HER2 status, tumor biology, response to therapy, and overall health.
Access notes and questions to confirm
BorderFreeHealth connects U.S. patients with licensed Canadian partner pharmacies. Where required, prescription details are verified with the prescriber before dispensing by the pharmacy. This can support cash-pay prescription access for eligible patients without insurance, while availability and eligibility may vary.
Before choosing a product page or resource, confirm the exact medicine name, strength, schedule, and purpose with the treating clinician. Similar names can cause confusion, especially across aromatase inhibitors, endocrine therapy options, and targeted medicines. Ask whether the plan is adjuvant, neoadjuvant, metastatic, or maintenance-focused.
Useful questions to bring to a visit include:
- Which receptor results are driving this plan: ER positive, PR positive, or both?
- Is HER2 status changing the recommended pathway?
- Is the goal recurrence reduction, tumor control, symptom control, or another goal?
- Will any labs, scans, ECGs, or symptom checks be scheduled?
- Which side effects should be reported promptly?
Related browsing paths
The Cancer Products category is a broader product list when you need to move beyond HR positive breast cancer. Stay within condition-specific pages when receptor status matters most, and use product pages when you already know the medicine name from a prescription or care plan.
This page is best used as a starting map. Compare the class, form, monitoring needs, and related condition page before opening individual listings. Then bring any questions back to your oncology team, especially when test results or treatment goals change.
This content is for informational purposes only and is not a substitute for professional medical advice.
Filter
Product price
Product categories
Conditions
Select options
This product has multiple variants. The options may be chosen on the product page
Frequently Asked Questions
What does hormone receptor positive mean on a breast cancer report?
It means the cancer cells have estrogen receptors, progesterone receptors, or both. Reports may use ER positive, PR positive, HR positive, or ER/PR positive language. These results help clinicians consider endocrine therapy, targeted add-ons, and related treatment pathways. Receptor status is only one part of planning, so stage, HER2 status, menopause status, prior treatment, and overall health also matter.
How should I compare products in this category?
Start with the medicine name and class from the care plan. Then compare form, product page details, handling needs, monitoring topics, and whether the therapy is used alone or in combination. For example, an aromatase inhibitor listing serves a different role than a CDK4/6 inhibitor listing. Confirm the exact product, strength, and schedule with the oncology team before making any medication changes.
Are CDK4/6 inhibitors the same as endocrine therapy?
No. Endocrine therapy lowers hormone activity or blocks hormone signaling. CDK4/6 inhibitors target cell-cycle pathways and may be used with endocrine therapy in some breast cancer regimens. Product pages for palbociclib, ribociclib, and abemaciclib-related options should be read as distinct medication listings. Your clinician can explain why a targeted add-on may or may not fit a specific case.
Is PR positive breast cancer good or bad?
PR positive status gives clinicians useful information, but it does not predict the whole outcome by itself. Prognosis depends on several details, including tumor stage, grade, ER status, HER2 status, lymph node findings, overall health, and response to treatment. Use this category to organize terms and related options, then ask the oncology team how the full pathology report affects the care plan.